SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI) -- Ignore unavailable to you. Want to Upgrade?


To: Jim Spitz who wrote (889)5/25/2001 11:11:20 AM
From: Starlight  Read Replies (1) | Respond to of 1154
 
You might want to read the fine print in the preceding post:

Pacific Equity Investigations is an equity valuation research center. It may and often does have positions that are consistent with its reports.
Anthony Elgindy, Director of Research , is a professional trader and analyst, and one of the most well known investment commentators on the
Internet. His work has been featured in numerous financial news media. He has appeared on TV on ABC’s "20/20" , CNBC , KUSI Channel 9 ,
MSNBC and Discovery Channel’s "Justice Files" . He is the subject of two recent books and has been featured in almost every financial
publication in the Country, His mission involves speaking out to warn the public about the risks of fraud and overvalued equities.


Isn't this the guy who did jail time for securities violations? (I don't remember the exact details.)



To: Jim Spitz who wrote (889)5/25/2001 1:01:10 PM
From: OldAIMGuy  Respond to of 1154
 
Here's what's listed on SI. It doesn't seem to combine well with Insidetruth.com. Like mixing oil and water.
siliconinvestor.com
I got a feeling the Insidetruth.com guys were reading from the wrong columns.

This doesn't mean I put any faith in what analysts have to say. In fact I don't listen or read their stuff at all. That said, I do use Value Line for statistical information, not their opinions. I can't remember if VL's expanded edition has GENE in it.

Best regards, Tom



To: Jim Spitz who wrote (889)5/25/2001 2:34:42 PM
From: Starlight  Read Replies (1) | Respond to of 1154
 
Total cash decreased because of purchase of Marketable Securities (which increased by about $27K over the prior report):

RE: Corporate Filings show the following:

Total cash and equivalents decreased from over 52 million to less than 22 million in the preceding 12 month period


(Check the financials at the company's website:)

ccbn.secinfo.com.

At August 31, 2000 and February 24, 2001, the Company's cash, cash equivalents
and marketable securities consisted of the following:

· Download Table

August 31, February 24,
2000 2001
---- ----

Cash and Cash Equivalents:
Cash .................................. $42,211,172 $21,115,572
Debt securities ....................... 9,900,000 501,032
----------- -----------
Total cash and cash equivalents $52,111,172 $21,616,604
=========== ===========
Marketable Securities:
Short-term securities ................. $22,348,841 $40,422,234
----------- -----------
Long-term securities .................. 1,224,184 9,584,205
=========== ===========
Total marketable securities ... $23,573,025 $50,006,439
=========== ===========

The Company has $200,000 in restricted cash in connection with certain long-term
obligations (see Note 8).



To: Jim Spitz who wrote (889)5/25/2001 3:00:46 PM
From: zurdo  Respond to of 1154
 
Old Anthony Elgindy rides again!!! Ooh, Anthony now bills himself as a Jim Cramer lookalike!! I see he hasn't lost his flair for alarmist "warnings" about stocks he and his group are most probably shorting. Anthony is, in my opinion, a notorious short seller and manipulator who uses his group of short sellers to bring down a stock with negative BS and scare tactics. No doubt his group is short GENE. Of course, to Anthony and his group anything positive analyst statement about GENE, such as a target of $84, would be looked upon as "stupid".



To: Jim Spitz who wrote (889)5/29/2001 1:34:39 AM
From: zurdo  Read Replies (2) | Respond to of 1154
 
Jim Spitz, the only reason you think the analyst's $84 price target for GENE is stupid is that you are short GENE, and you haven't covered. You are one worried short seller!!